This is a new paper that we think helps to clarify how photobiomodulation should be viewed as an adjunctive or combination therapy. Its use as a way to activate biochemical and nanoparticle-based therapeutics is a direct pairing of noninvasive and more invasive therapeutic strategies. We have studied, validated and are now combining PBM with neurofeedback and TDCS/TACS for dementing illnesses as well as movement disorders and traumatic brain injuries. This is definitely the beginning of what will be growing trend as Pharma expands its position in both digital neurotherapeutics and electroceuticals.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.